{
  "event_id": "cc32a78dce87",
  "ticker": "OPTN",
  "company_name": "OptiNose",
  "drug_name": "XHANCE fluticasone propionate",
  "pdufa_date": "20200423",
  "approval_type": {
    "status": "found",
    "value": "nda",
    "source": "websearch:NAVIGATE Phase 3 (Approved Sep 2017, Mar 2024 CRS)",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.523884",
    "error": null
  },
  "indication": {
    "status": "found",
    "value": "Nasal polyps/CRS",
    "source": "websearch:NAVIGATE Phase 3 (Approved Sep 2017, Mar 2024 CRS)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.523885",
    "error": null
  },
  "generic_name": {
    "status": "found",
    "value": "fluticasone propionate",
    "source": "websearch_fda",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:34:43.330127",
    "error": null
  },
  "therapeutic_area": {
    "status": "found",
    "value": "Respiratory",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T10:49:58.979947",
    "error": null
  },
  "phase": {
    "status": "found",
    "value": "Approved",
    "source": "websearch_clinical",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:34:43.330127",
    "error": null
  },
  "primary_endpoint_met": {
    "status": "found",
    "value": true,
    "source": "websearch:NAVIGATE Phase 3 (Approved Sep 2017, Mar 2024 CRS)",
    "confidence": 0.95,
    "evidence": [
      "NAVIGATE Phase 3 (Approved Sep 2017, Mar 2024 CRS)"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.523871",
    "error": null
  },
  "p_value": {
    "status": "not_applicable",
    "value": null,
    "source": "websearch:NAVIGATE Phase 3 (Approved Sep 2017, Mar 2024 CRS)",
    "confidence": 0.9,
    "evidence": [
      "Single-arm or accelerated approval - no comparator p-value"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.523878",
    "error": null
  },
  "p_value_numeric": null,
  "effect_size": {
    "status": "found",
    "value": "Significant nasal congestion/polyp reduction",
    "source": "websearch:NAVIGATE Phase 3 (Approved Sep 2017, Mar 2024 CRS)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.523880",
    "error": null
  },
  "safety_signal": {
    "status": "found",
    "value": false,
    "source": "default_for_approved",
    "confidence": 0.9,
    "tier": 1,
    "note": "No blocking safety signals at approval"
  },
  "phase3_study_names": [
    "A 16-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety",
    "A 16-Week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (Bid) Using a Novel Bi-directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-week, Open-label Extension Phase to Assess Safety",
    "An Open-Label, 2-Part, Randomized, Crossover Study to Compare the Bioavailability of Intranasal Administration of 200 and 400 µg of OPTINOSE™ FLUTICASONE With 400 µg of Flonase® (Fluticasone Propionate) Nasal Spray (Part 1), and Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2) (Current Investigation is Part 2 Only)",
    "Hypertonic Versus Isotonic Saline Irrigations for Chronic Rhinosinusitis"
  ],
  "nct_ids": [
    "NCT01622569",
    "NCT01624662",
    "NCT02266927",
    "NCT04242368"
  ],
  "enrollment": {
    "count": 323,
    "type": "ACTUAL",
    "nct_id": "NCT01622569",
    "source": "clinicaltrials.gov",
    "fetched_at": "2026-01-10T17:29:06.127807"
  },
  "has_prior_crl": {
    "status": "found",
    "value": false,
    "source": "derived_from_first_submission",
    "confidence": 0.95,
    "tier": 2
  },
  "prior_crl_reason": null,
  "is_resubmission": {
    "status": "found",
    "value": 0,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "pai_passed": {
    "status": "found",
    "value": true,
    "source": "derived_from_approval",
    "confidence": 0.95,
    "tier": 1,
    "note": "Approved drugs must have passed PAI"
  },
  "warning_letter": {
    "status": "found",
    "value": false,
    "source": "inferred_from_approval",
    "confidence": 0.8,
    "tier": 2,
    "note": "Approved drugs unlikely to have blocking warning letters"
  },
  "result": "approved",
  "data_quality_score": 0.075,
  "collected_at": "2026-01-09T00:24:33.766467",
  "enriched_at": "2026-01-11T19:49:11.100108",
  "needs_manual_review": false,
  "review_reasons": [],
  "original_case_id": "d7438213bc40",
  "fda_designations": {
    "breakthrough_therapy": false,
    "fast_track": false,
    "priority_review": false,
    "orphan_drug": false,
    "accelerated_approval": false
  },
  "mechanism_of_action": "Corticosteroid",
  "adcom_info": {
    "scheduled": false,
    "held": false,
    "outcome": null,
    "vote": null
  },
  "days_to_pdufa": -2088,
  "pdufa_status": "past",
  "risk_tier": "HIGH",
  "days_calculated_at": "2026-01-10T16:59:41.273527",
  "adcom_scheduled": {
    "value": false,
    "status": "confirmed_none",
    "source": "websearch_adcom",
    "confidence": 0.7,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:43:02.939952"
  },
  "adcom_vote_ratio": {
    "value": null,
    "status": "not_applicable",
    "source": "websearch_adcom",
    "confidence": 0.6,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:43:02.939960"
  },
  "breakthrough_therapy": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:48:45.651523",
    "search_status": "CONFIRMED_NONE"
  },
  "orphan_drug": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:48:52.199132",
    "search_status": "CONFIRMED_NONE"
  },
  "priority_review": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:48:58.506981",
    "search_status": "CONFIRMED_NONE"
  },
  "fast_track": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:49:05.290912",
    "search_status": "CONFIRMED_NONE"
  },
  "accelerated_approval": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:49:11.100077",
    "search_status": "CONFIRMED_NONE"
  }
}